Strong Revenue Growth
Forian reported a second quarter revenue of $7.5 million, representing a 56% year-over-year growth. This growth was driven largely by the Kyber Data Science acquisition and new pharma projects.
Improved Financial Metrics
The company achieved a net income of $224,000 and adjusted EBITDA of $591,000, improving from a loss of $2.5 million and positive $78,000 year-over-year, respectively.
Kyber Data Science Acquisition Impact
The full quarter impact of the Kyber Data Science acquisition contributed approximately $1.9 million or 39% to the revenue growth, enhancing the company's data capabilities and product offerings.
Strategic Growth and Market Positioning
Forian's acquisition and integration of diverse clinical data sources have strengthened its market position with analytics-ready solutions, enhancing its competitive advantage.
Positive Full Year Outlook
Forian reaffirmed its outlook for full year 2025 revenue of $28 million to $30 million, indicating a projected growth of 39% to 49% year-over-year.